title: Reply: Management of De Novo CML and Imatinib-Induced Acute Rhabdomyolysis With the Second-Generation TKI, Dasatinib.
authors: Umit Y
authors: UY
authors: Malkan
authors: Gursel
authors: G
authors: Gunes
authors: Sezgin
authors: S
authors: Etgul
authors: Tuncay
authors: T
authors: Aslan
authors: Seda
authors: S
authors: Aydin
authors: Ibrahim C
authors: IC
authors: Haznedaroglu